Macimorelin 1MG Capsule

Macimorelin 1 mg Capsule is an orally active growth hormone secretagogue and ghrelin receptor (GHS-R1a) agonist used primarily in diagnostic endocrinology. It mimics the action of the endogenous hormone ghrelin, stimulating the pituitary gland to release growth hormone (GH). Unlike injectable agents, macimorelin is notable for its oral bioavailability, making it a convenient option for growth hormone stimulation testing. Macimorelin is FDA-approved (as Macrilen) for the diagnosis of adult growth hormone deficiency (AGHD). During testing, it is administered as a single oral dose, and GH levels are measured over time to assess pituitary function. This provides a safer and more patient-friendly alternative to traditional stimulation tests such as insulin-induced hypoglycemia. A 1 mg capsule represents a compounded or research-based dosing format, as standard diagnostic dosing is typically weight-based and administered in a controlled clinical setting. Macimorelin works by binding to ghrelin receptors in the hypothalamus and pituitary, triggering a physiologic cascade that leads to GH secretion. Clinical studies have demonstrated that macimorelin is a reliable and well-tolerated diagnostic agent for AGHD, with comparable accuracy to traditional testing methods. https://pubmed.ncbi.nlm.nih.gov/28973338/ Additional FDA and clinical pharmacology data confirm its mechanism as a ghrelin receptor agonist used in GH stimulation testing: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf Because it directly influences hormone release, macimorelin should be used only und